

Recommendations updated for H. pylori treatment in adults

July 12 2016



(HealthDay)—Recommendations have been updated for treatment of



Helicobacter pylori in adults, according to a consensus statement published in the July issue of Gastroenterology.

Carlo A. Fallone, M.D., from the McGill University Health Centre in Montreal, and colleagues conducted a systematic literature review and developed specific, updated recommendations for eradication therapy in adults with *H. pylori* infection.

The researchers strongly recommend that all *H. pylori* regimens should be given for 14 days because of the increasing failure of therapy. Concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline [PBMT]) were included as recommended first-line strategies. Use of PPI triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) should be limited to regions with low resistance to clarithromycin or high eradication success with these regimens. PBMT and levofloxacin-containing therapy were included as recommended rescue therapies. Rifabutin therapy should be used only for patients who have failed to respond to three or more previous treatment regimens.

"Optimal treatment of *H. pylori* infection requires careful attention to local antibiotic resistance and eradication patterns," the authors write. "The quadruple therapies PAMC or PBMT should play a more prominent role in eradication of *H. pylori* infection, and all treatments should be given for 14 days."

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract

Full Text (subscription or payment may be required)



Copyright © 2016 <u>HealthDay</u>. All rights reserved.



Citation: Recommendations updated for H. pylori treatment in adults (2016, July 12) retrieved 9 April 2024 from https://medicalxpress.com/news/2016-07-pylori-treatment-adults.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.